Global Drug-Eluting Stents Market Size By Type (Rapamycin, Paclitaxel), By Application (Angina Pectoris, Myocardial Infarction), By Region, And Segment Forecasts, 2023 to 2032

lobal Drug-Eluting Stents Market Report Description

The Global Drug-Eluting Stents Market was valued at USD 6.4 billion in 2023 and is projected to reach USD 11.1 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2023–2031). The market's expansion is primarily fueled by the increasing prevalence of cardiovascular diseases, the rising adoption of minimally invasive procedures, and continuous advancements in stent technology. Drug-eluting stents (DES) have significantly improved patient outcomes by reducing restenosis rates compared to bare-metal stents, making them the preferred choice in coronary interventions globally.

Drivers:

1. Rising Incidence of Cardiovascular Diseases:

Cardiovascular conditions, including coronary artery disease, are leading causes of morbidity and mortality worldwide. The growing aging population, sedentary lifestyles, and unhealthy dietary habits are contributing to a surge in cardiovascular interventions, boosting the demand for DES.

2. Technological Advancements in Stent Design and Materials:

Innovations such as biodegradable polymers, next-generation antiproliferative drugs, and thinner strut designs are enhancing the efficacy and safety profile of DES, fostering greater adoption among healthcare providers.

3. Preference for Minimally Invasive Procedures:

Minimally invasive techniques are gaining traction due to their reduced recovery time and lower procedural risks. DES enable effective treatment through percutaneous coronary interventions (PCI), aligning with this trend.

Restraints:

1. High Cost of Drug-Eluting Stents:

The relatively high cost of DES compared to bare-metal stents or other alternative therapies may hinder market growth, especially in low- and middle-income countries with limited reimbursement frameworks.

2. Regulatory and Product Recall Challenges:

The DES market is subject to stringent regulatory scrutiny, and instances of product recalls or safety concerns may impact consumer confidence and slow down adoption rates.

Opportunity:

1. Expansion into Emerging Markets:

Developing countries are witnessing improvements in healthcare infrastructure and access to interventional cardiology procedures. Market players can tap into these regions by offering affordable and advanced DES solutions.

2. Growing Demand for Biodegradable and Dual Therapy Stents:

Biodegradable stents and dual therapy stents (which combine antiproliferative and endothelial-promoting drugs) represent the next frontier in coronary intervention, offering significant market potential for innovative players.

Market by System Type Insights:

The polymer-based drug-eluting stents segment held the dominant market share in 2023. These stents are widely adopted due to their proven efficacy and ability to deliver drugs in a controlled manner. However, polymer-free and bioresorbable stents are gaining popularity, supported by ongoing R&D and favorable clinical outcomes, and are expected to experience the fastest growth during the forecast period.

Market by End-use Insights:

In 2023, hospitals emerged as the largest end-use segment, accounting for over 60% of the market share. The availability of skilled professionals, infrastructure for advanced cardiac procedures, and reimbursement support make hospitals the preferred setting for DES implantation. Ambulatory surgical centers are also witnessing increased demand due to lower procedural costs and improved outpatient care models.

Market by Regional Insights:

North America led the global drug-eluting stents market in 2023, owing to high healthcare spending, early adoption of advanced technologies, and the presence of major players. Meanwhile, the Asia-Pacific region is projected to register the highest CAGR, driven by a rising geriatric population, increasing prevalence of heart disease, and expanding access to cardiovascular care in countries like India and China.

Competitive Scenario:

Key players operating in the Global Drug-Eluting Stents Market include Boston Scientific Corporation, Abbott Laboratories, Medtronic plc, BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, MicroPort Scientific Corporation, and Biosensors International Group. These companies are focused on product innovation, clinical trials, and strategic collaborations to gain a competitive edge.

Recent Developments:

In March 2024, Abbott launched its latest-generation Xience Sierra stent in new international markets, designed for complex cases.

In November 2023, Boston Scientific received expanded FDA approval for its Synergy XD bioabsorbable polymer stent system.

In 2022, Medtronic announced the acquisition of a novel stent platform to enhance its DES portfolio aimed at high-risk PCI procedures.

Scope of Work – Global Drug-Eluting Stents Market

Report Metric Details

Market Size (2023) USD 6.4 billion

Projected Market Size (2031) USD 11.1 billion

CAGR (2023–2031) 7.2%

Key Segments by System Type Polymer-Based DES, Polymer-Free DES, Bioresorbable Stents

Key Segments by End-Use Hospitals, Ambulatory Surgical Centers

Leading Region North America

Key Players Abbott, Boston Scientific, Medtronic, BIOTRONIK, Terumo

Key Market Developments:

March 2024 – Abbott launches advanced DES technology in emerging markets to improve access to PCI.

November 2023 – Boston Scientific expands clinical data supporting its Synergy XD stent line.

August 2022 – Medtronic integrates AI with DES imaging platforms for enhanced precision.

FAQs

1) What is the current market size of the Global Drug-Eluting Stents Market?

The market size was valued at USD 6.4 billion in 2023.

2) What is the major growth driver of the Global Drug-Eluting Stents Market?

The rising incidence of cardiovascular diseases and demand for minimally invasive interventions are key drivers.

3) Which is the largest region during the forecast period in the Global Drug-Eluting Stents Market?

North America holds the largest share due to advanced healthcare infrastructure and early adoption.

4) Which segment accounted for the largest market share in the Global Drug-Eluting Stents Market?

The polymer-based drug-eluting stents segment led the market in 2023.

5) Who are the key market players in the Global Drug-Eluting Stents Market?

Key players include Abbott, Boston Scientific, Medtronic, BIOTRONIK, and Terumo.

Would you like this formatted into a downloadable Word document or PDF?